Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Invion ( (AU:IVX) ).
Invion Limited has announced a pro-rata non-renounceable offer of Loyalty Options to eligible shareholders as part of its capital management and clinical development strategy. The proceeds from this offer will support ongoing research and development, including a Phase I/II trial for anogenital cancer in collaboration with the Peter MacCallum Cancer Centre. This initiative is expected to raise up to $1 million initially, with potential for an additional $16 million if all options are exercised, bolstering Invion’s efforts to expand its clinical pipeline and enhance its market positioning.
More about Invion
Invion Limited is a company operating in the biotechnology industry, focusing on developing next-generation treatments using its Photosoft™ technology. The company is involved in clinical trials for non-melanoma skin cancer and anogenital cancer, aiming to advance therapeutic and diagnostic solutions, particularly in combination with immune checkpoint inhibitors for challenging cancers.
Average Trading Volume: 97,676
Technical Sentiment Signal: Sell
Current Market Cap: A$10.17M
For a thorough assessment of IVX stock, go to TipRanks’ Stock Analysis page.